Media stories about Adamis Pharmaceuticals (NASDAQ:ADMP) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adamis Pharmaceuticals earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.0935641849089 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
Several research firms have recently issued reports on ADMP. Raymond James Financial began coverage on shares of Adamis Pharmaceuticals in a research note on Tuesday, September 12th. They set an “outperform” rating and a $7.00 target price on the stock. B. Riley reissued a “buy” rating and set a $9.50 target price on shares of Adamis Pharmaceuticals in a research note on Wednesday, October 4th. ValuEngine lowered shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Maxim Group reissued a “buy” rating and set a $13.00 target price on shares of Adamis Pharmaceuticals in a research note on Monday, August 21st. Finally, Zacks Investment Research lowered shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 20th. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. Adamis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $10.00.
Shares of Adamis Pharmaceuticals (ADMP) opened at $4.00 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.79 and a current ratio of 3.93. Adamis Pharmaceuticals has a 12 month low of $2.55 and a 12 month high of $6.45.
ILLEGAL ACTIVITY WARNING: “Adamis Pharmaceuticals (ADMP) Given Media Sentiment Score of 0.11” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/12/05/adamis-pharmaceuticals-admp-given-media-sentiment-score-of-0-11.html.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.